MARKET

PRTA

PRTA

Prothena Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

52.35
+4.15
+8.61%
Opening 15:36 07/28 EDT
OPEN
47.89
PREV CLOSE
48.20
HIGH
52.98
LOW
47.89
VOLUME
233.78K
TURNOVER
--
52 WEEK HIGH
67.08
52 WEEK LOW
9.67
MARKET CAP
2.31B
P/E (TTM)
-16.8512
1D
5D
1M
3M
1Y
5Y
Is Prothena Corporation plc (PRTA) A Good Stock To Buy?
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a s...
Insider Monkey · 2d ago
BRIEF-Prothena Presents New Data From Alzheimer’s Portfolio
reuters.com · 2d ago
Prothena presents new data from Alzheimer’s portfolio at AAIC 2021
travellinglight/iStock via Getty Images Prothena (PRTA) presents new data at the AAIC 2021 from two of its Alzheimer’s disease ((AD)) programs. The presentations highlight new data for PRX012, the next-generation anti-amyloid
Seekingalpha · 2d ago
Prothena Highlights Presentation Of New Data From Alzheimer's Portfolio At Alzheimer's Association International Conference 2021
Late-breaking PRX012 poster highlights significant ex vivo clearance of both pyroglutamate-modified and -unmodified Aβ plaque from AD brain at concentrations expected to be reached in CNS with
Benzinga · 2d ago
Prothena Presents New Data from Robust Alzheimer's Portfolio at the Alzheimer's Association International Conference 2021
- Late-breaking PRX012 poster highlights significant ex vivo clearance of both pyroglutamate-modified and -unmodified AB plaque from AD brain at concentrations expected to be reached in CNS with subcutaneous administration
Globe Newswire · 2d ago
Prothena To Present Data From Two Of Its Alzheimer's Disease Programs At Alzheimer's Association International Conference 2021 Jul. 26
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that it will present
Benzinga · 07/20 20:10
BRIEF-Prothena To Present Data From Two Of Its Alzheimer’S Disease Programs At The Alzheimer’S Association International Conference 2021
reuters.com · 07/20 20:08
Prothena to Present Data from Two of its Alzheimer's Disease Programs at the Alzheimer's Association International Conference 2021
DUBLIN, Ireland, July 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that it will p...
Globe Newswire · 07/20 20:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRTA. Analyze the recent business situations of Prothena Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRTA stock price target is 68.63 with a high estimate of 76.00 and a low estimate of 57.00.
EPS
Institutional Holdings
Institutions: 210
Institutional Holdings: 42.25M
% Owned: 95.64%
Shares Outstanding: 44.18M
TypeInstitutionsShares
Increased
38
9.31M
New
21
2.37M
Decreased
47
3.25M
Sold Out
13
3.23M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+2.14%
Key Executives
Non-Executive Chairman/Independent Director
Lars Ekman
President/Chief Executive Officer/Director
Gene Kinney
Chief Financial Officer/Chief Operating Officer
Tran Nguyen
Chief Accounting Officer/Controller
Karin Walker
Chief Scientific Officer
Wagner Zago
Other
Hideki Garren
Other
Carol Karp
Other
Brandon Smith
Other
Radhika Tripuraneni
Secretary
Michael Malecek
Director
Sanjiv Patel
Independent Director
Paula Cobb
Independent Director
Richard Collier
Independent Director
Shane Cooke
Independent Director
K. Anders Harfstrand
Independent Director
Christopher Henney
Independent Director
Oleg Nodelman
Independent Director
Dennis Selkoe
No Data
About PRTA
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Webull offers kinds of Prothena Corporation PLC stock information, including NASDAQ:PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTA stock methods without spending real money on the virtual paper trading platform.